New drugs used alongside statins can lower LDL cholesterol to really low levels, but do the risks outweigh the benefits? Cholesterol ratio can give you additional information about your heart disease risk. Learn what your numbers mean and how to use them to tailor your….
Cholesterol is an important topic for heart health. We explain just how much cholesterol you should have each day and where fats fit in.
HDL cholesterol removes extra cholesterol and plaque buildup in your arteries. Here are six other exercises that can help improve your levels too. If you have diabetes, you have a higher risk of developing high cholesterol. High triglycerides can have many causes, including genetics. When it's an inherited condition, it's known as familial hypertriglyceridemia.
Health Conditions Discover Plan Connect. CoQ10 levels and statin side effects. Possible benefits of CoQ10 supplements. Other considerations. The bottom line. Read this next. Medically reviewed by Alana Biggers, M. Medically reviewed by Deborah Weatherspoon, Ph. At this time, coenzyme Q10 isn't universally recommended for preventing side effects from cholesterol-lowering drugs known as statins. Although statins are well tolerated by most people, they can cause muscle and joint aches.
Statins have been found to reduce the amount of naturally occurring coenzyme Q10 in the body. Because coenzyme Q10 plays a role in muscle cell energy production, some researchers have proposed that taking a coenzyme Q10 supplement might reduce the risk of muscle-related side effects. Scientific studies to determine the effectiveness of coenzyme Q10 in reducing statin-related muscle pain have had mixed results.
Some studies show a benefit, while other studies show no effect. Because coenzyme Q10 doesn't cause side effects for most people, your doctor might suggest a trial of it to see if it helps. Your doctor might also decrease the dose of your statin, try a different statin or switch you to a different type of cholesterol-lowering medication entirely. There is a problem with information submitted for this request. Sign up for free, and stay up-to-date on research advancements, health tips and current health topics, like COVID, plus expert advice on managing your health.
Error Email field is required. Error Include a valid email address. To provide you with the most relevant and helpful information and to understand which information is beneficial, we may combine your e-mail and website usage information with other information we have about you. If we combine this information with your PHI, we will treat all of that information as PHI, and will only use or disclose that information as set forth in our notice of privacy practices.
You may opt-out of e-mail communications at any time by clicking on the Unsubscribe link in the e-mail. Our Housecall e-newsletter will keep you up-to-date on the latest health information.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission. Any use of this site constitutes your agreement to the Terms and Conditions and Privacy Policy linked below. Mayo Clinic is a nonprofit organization and proceeds from Web advertising help support our mission.
Mayo Clinic does not endorse any of the third party products and services advertised. A single copy of these materials may be reprinted for noncommercial personal use only.
This content does not have an English version. This content does not have an Arabic version. See more conditions. Patients were excluded if any of the following criteria were present: acute coronary syndrome developing in the last month; active myocarditis; active pericarditis; uncontrolled hypertension; hepatic failure Child B, C ; pulmonary or renal failure; and heart failure with KILLIP classification 3 and 4.
Written informed consents were obtained from all patients for authorized use of their medical records for research purposes. Moreover, the protocol was approved by the ethical committee of our university. This study was a double blind trial. For the purpose of blindness of patients, placebo was made with the same shape and size of the actual drugs, and for the blindness of physicians the drugs were delivered to patients by one of the study investigators who did not perform the echocardiography and determination of NYHA FC grade.
Patients who enrolled in the study were randomly divided into 2 groups, using Random Allocation Software the sequence generation was performed by one of the study investigators who did not play a role in the clinical assessments and drug delivery to patients.
In the other group placebo , patients received 10 mg atorvastatin daily and the placebo of CoQ10 pearl, with the same shape and size of the drug, for 4 months.
In both study groups, patients received standard CHF medication. The drugs were delivered to patients by one of the study investigators. The dose of drugs used in this study was determined according to previous studies performed in this field.
In all patients, baseline data including age, sex, weight, history of diabetes and myocardial infarction, previous use of beta blockers, and ACEI were collected. EF and cardiac index CI were determined. Glomerular filtration rate GFR was calculated. After the study period 4 months , echocardiography was repeated by the same device and the same investigator, NYHA FC was calculated for the second time, and laboratory tests were checked again in the same laboratory in which previous tests had been performed.
The primary outcome of this study was the effect of the addition of the atorvastatin and CoQ10 combination supplement to standard regiment on cardiac EF, in comparison with atorvastin and placebo.
During the period of the project a total number of 62 patients were enrolled in the study. Demographic data in both study groups are shown and compared in table 1. There was no statistically significant difference in study parameters between the groups.
All patients had used ACEI and beta blocker before the study began. After 4 months, all patients were alive and came back for follow up.
Other parameter changes did not differ significantly between the study groups. Detailed data are shown in table 2. Our study results showed that EF, as the primary outcome of the study, increased significantly in the intervention group in comparison with the placebo group. Among secondary outcomes, NYHA FC decreased significantly in the intervention group in comparison with the placebo group.
The effect of CoQ10 on EF can be explained in this way that CoQ10 reduces the reactive oxygen species which rise in heart failure; on other hand, CoQ10 reduces peripheral vascular resistance and improves the heart pomp to push blood.
In a meta-analyses performed by sander et al. Previous studies mentioned that CoQ10 supplement improves lipid profile. Shojaei et al. In line with our study, the study by Okello et al. Our study also had a limitation; the follow up in our study was 4 months. Furthermore, studies with longer follow up period are recommended in order to evaluate survival rate. In conclusion, we deduce that the combination of atorvastatin and CoQ10 as an adjunctive treatment of heart failure increase EF and improve NYHA FC in comparison with single use of atorvastatin.
Conflicts of Interest. National Center for Biotechnology Information , U. ARYA Atheroscler.
0コメント